Memantine for fragile x-associated tremor/ataxia syndrome: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 75, Issue 3, 2014, Pages 264-271

  Seritan, Andreea L ^a   Nguyen, Danh V ^a   Mu, Yi ^a   Tassone, Flora ^a   Bourgeois, James A ^a   Schneider, Andrea ^a   Cogswell, Jennifer B ^a   Cook, Kylee R ^a   Leehey, Maureen A ^a   Grigsby, Jim ^a   Olichney, John M ^a   Adams, Patrick E ^a   Legg, Wendi ^a   Zhang, Lin ^a   Hagerman, Paul J ^a   Hagerman, Randi J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; PLACEBO;

ADULT; AGED; ARTICLE; BEHAVIORAL DYSCONTROL SCALE; CATSYS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NEUROLOGIC EXAMINATION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ATAXIA; DOUBLE-BLIND METHOD; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREMOR;

EID: 84898752958     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.13m08546     Document Type: Article

References (75)

1. Hagerman PJ. The fragile X prevalence paradox. Med Genet. 2008;45(8):498-499.
2. Tassone F, long KP, Tong TH, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100.
3. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am J Med Genet. 1999;83(4):322-325.
4. Sullivan AK, Marcus M, Epstein MP, et al. Association oiFMRl repeat size with ovarian dysfunction. Hum Reprod. 2005;20(2):402-412.
5. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am JHum Genet. 2000;66(1):6-15.
6. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57(1):127-130.
7. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am JHum Genet. 2003;72(4):869-878.
8. Roberts JE, Bailey DB Jr, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):130-139.
9. Sevin M, Kutalik Z, Bergman S, et al. Penetrance of marked cognitive impairment in older male carriers of the FMR1 gene premutation. Med Genet. 2009;46(12):818-824.
10. Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. Clin Psychiatry. 2011;72(2):175-182.
11. Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A. 2012;158A(10):2473-2481.
12. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004;291(4):460-469.
13. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A(8):1009-1016.
14. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, et al. Penetrance oiFMRl premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009;17(10):1359-1362.
15. Hall D, Tassone F, Klepitskaya O, et al. Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012;27(2):296-300.
16. Seritan AL, Nguyen DV, Farias ST, et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1138-1144.
17. Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009;57(8):830-836.
18. Juncos JL, Lazarus JT, Graves-Allen E, et al. New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS). Neurogenetics. 2011;12(2):123-135.
19. Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurobgy. 2012;79(18):1898-1907.
20. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard DevDisabil Res Rev. 2004;10(1):25-30.
21. Bacalman S, Farzin F, Bourgeois JA, et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. Clin Psychiatry. 2006;67(1):87-94.
22. Leehey MA, Berry-Kravis E, Min SJ, et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007;22(2):203-206.
23. Brega AG, Reynolds A, Bennett RE, et al. Functional status of men with the fragile X premutation, with and without the tremor/ataxia syndrome (FXTAS). Int J Geriatr Psychiatry. 2009;24(10):1101-1109.
24. Thomas SJ, Grossberg GT Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging. 2009;4:367-377.
25. Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc NatlAcadSci USA. 1995;92(16):7162-7166.
26. Reisberg B, Doody R, Stoffler A, et al; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
27. Zajaczkowski W, Frankiewicz T, Parsons CG, et al. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology. 1997;36(7):961-971.
28. Frankiewicz T, Pile A, Parsons CG. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology. 2000;39(4):631-642.
29. Cao Z, Hulsizer S, Tassone F, et al. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet. 2012;21(13):2923-2935.
30. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2) :CD003154.
31. Mobius HJ, Stoffler A. Memantine in vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):207-213.
32. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 201 l;26(suppl 3):S42-S80.
33. Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci Rep. 2012;12(5):492-501.
34. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord. 2010;25(4):508-510.
35. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs. 2010;24(9):729-739.
36. Collins S, Sigtermans MJ, Dahan A, et al. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med. 2010;11(11):1726-1742.
37. Sani G, Serra G, Kotzalidis GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current predinical and clinical evidence. CNS Drugs. 2012;26(8):663-690.
38. Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012;14(1):64-70.
39. Hanney M, Prasher V, Williams N, et al; MEADOWS trial researchers. Memantine for Dementia in Adults Older Than 40 Years With Down's Syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9815):528-536.
40. Boada R, Hutaff-Lee C, Schrader A, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012;2(7):el41.
41. Ortigas MC, Bourgeois JA, Schneider A, et al. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. Clin Psychopharmacol. 2010;30(5):642-644.
42. Despres C, Lamoureux D, Beuter A. Standardization of a neuromotor test battery: the CATSYS system. Neurotoxicology. 2000;21(5):725-735.
43. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometric Research, New York State Psychiatric Institute; 2002.
44. Wechsler D. Wechsler Adult Intelligence Scale-Third Edition: Administration and Scoring Manual. San Antonio, TX: Harcourt Assessment; 1997.
45. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Psychiatr Res. 1975;12(3):189-198.
46. Grigsby J, Kaye K, Robbins LJ. Reliabilities, norms and factor structure of the Behavioral Dyscontrol Scale. Percept Mot Skills. 1992;74(3 pt 1):883-892.
47. Delis D, Kramer J, Kaplan E, et al. The California Verbal Learning Test. San Antonio, TX: The Psychological Corporation; 1987.
48. Spreen O, Benton AL. Neurosensory Center Comprehensive Examination for Aphasia. Revised Edition. Victoria, BC: University of Victoria Neuropsychology Laboratory; 1977.
49. Wechsler D. Wechskr Memory Scale. 3rd ed. San Antonio, TX: Harcourt Assessment; 1997.
50. Grigsby J, Brega AG, Jacquemont S, et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). JNeurol Sci. 2006;248(1-2):227-233.
51. Grigsby J, Brega AG, Leehey MA, et al. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Mov Disord. 2007;22(5):645-650.
52. Grigsby J, Brega AG, Engle K, et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychobgy. 2008;22( 1) :48-60.
53. Allen EG, Juncos J, Letz R, et al. Detection of early FXTAS motor symptoms using the CATSYS computerised neuromotor test battery. JMed Genet. 2008;45(5):290-297.
54. Aguilar D, Sigford KE, Soontarapornchai K, et al. A quantitative assessment of tremor and ataxia in FMR1 premutation carriers using CATSYS. Am J Med Genet A. 2008;146A(5):629-635.
55. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:94-98.
56. Tassone F, Pan R, Amiri K, et al. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. Mol Diagn. 2008;10(1):43-49.
57. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE. 2012;7(5):e35185.
58. Jones R, Sheehan B, Phillips P, et al; DOMINO-AD team. DOMINO-AD protocol: Donepezil and Memantine in Moderate to Severe Alzheimer's Disease-a multicentre RCT. Trials. 2009;10(1):57.
59. Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149-156.
60. Ross-Inta CE, Omanska-Klusek A, Wong S, et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J. 2010;429(3):545-552.
61. Napoli E, Ross-Inta C, Wong S, et al. Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Hum Mol Genet. 2011;20(15):3079-3092.
62. Sellier C, Freyermuth F, Tabet R, et al. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 2013;3(3):869-880.
63. Karbowski M, Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Ada Neuropathol. 2012;123(2):157-171.
64. Napoli E, Wong S, Hung C, et al. Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington's disease. Hum Mol Genet. 2013;22(5):989-1004.
65. Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci. 2013;55:101-l 14.
66. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738-750.
67. Papapetropoulos S, Katzen HL, Scanlon BK, et al. Objective quantification of neuromotor symptoms in Parkinson's disease: implementation of a portable, computerized measurement tool. 2010:760196.
68. Hessl D, Tassone F, Loesch DZ, et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet. 2005;139B(1):115-121.
69. Psychiatric dementias associated with psychiatric disorders. In: Mendez MF, Cummings JL, eds. Dementia: A Clinical Approach. 3rd ed. Philadelphia, PA: Butterworth Heinemann; 2003:477-502.
70. Butters MA, Becker JT, Nebes RD, et al. Changes in cognitive functioning fo11owing treatment of late-life depression. Am J Psychiatry. 2000;157(12):1949-1954.
71. Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin IntervAging. 2008;3(2):251-262.
72. Berry-Kravis E, Hall DA, Leehey MA, et al. Treatment and management of FXTAS. In: Tassone F, Berry-Kravis EM, eds. The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS). New York, NY: Springer; 2010:137-154.
73. Seritan AL, Ortigas M, Seritan S, et al. Psychiatric disorders associated with FXTAS. Curr Psychiatry Rev. 2013;9(1):59-64.
74. Bourgeois JB, Farzin F, Brunberg JA, et al. Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine. J Neuropsychiatry Clin Neurosci. 2006;18(2):171-177.
75. Tariot PN, Farlow MR, Grossberg GT, et al; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324